Page 7 - Thomask Equels News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

AIM ImmunoTech Inc (NYSE:AIM) CEO Thomas K. Equels joined Proactives Stephen Gunnion to share an overview of the companys Pancreatic Cancer Program with...

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and...

LQwD Fintech Corp, a lightning network service provider, said it has appointed Aziz Pulatov as its chief technology officer. Pulatov has extensive...

Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions - Including a Potential Hostile Takeover of the Company - and Prevent Group from Continued Violations of Federal Securities

AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid GlobeNewswire July 18, 2022 Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities Laws and...

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25th

Further expansion of patent portfolio supports of the Company's extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the NetherlandsOCALA, Fla.

Water Tower Research LLC said it is hosting a Fireside Chat with Flotek Industries chairman, CEO and president John Gibson on May 25, 2022, at 11am EDT....

Water Tower Research LLC said it is hosting a Fireside Chat with Flotek Industries chairman, CEO and president John Gibson on May 25, 2022, at 11am EDT....